This Article  • Full text  • PDF  • Correction  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Kahn and colleagues¹ claimed that after a disagreement between them and the sponsor, they published the incomplete, although generally negative, results of a trial of an immunologic modifier (Remune; The Immune Response Corp [IRC], Carlsbad, Calif) for human immunodeficiency virus (HIV) "to fulfill our responsibility to inform patients of the outcome of this study, and to contribute to their understanding of HIV-1 Immunogen if it was to be studied in another clinical trial." I find that the article is inconclusive for several reasons.

First, while the primary end point of the study was time to HIV progression, the authors only presented HIV progression rate. They did not include true temporal variables, such as mean (or median) time to HIV progression for each treatment group, or time at which a certain proportion of patients experienced HIV progression for each treatment group.

Second, the viral load data could . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Evaluation of HIV-1 Immunogen, an Immunologic Modifier, Administered to Patients Infected With HIV Having 300 to 549 x 10⁶/L CD4 Cell Counts: A Randomized Controlled Trial
James O. Kahn, Deborah Weng Cherng, Kenneth Mayer, Henry Murray, Stephen Lagakos, and for the 806 Investigator Team
JAMA. 2000;284(17):2193-2202.
ABSTRACT | FULL TEXT